Want to land a Big Pharma deal? Be transparent, bring strong data and don't spam executives on LinkedIn. Dealmakers from GSK, Lilly, J&J, Bayer and Merck shared their advice at Fierce's London event. fiercebiotech.com/biotech/what-m…
FierceBiotech
Verified account This account is verified. Learn more@FierceBiotech
The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.
614 Following 103K Followers 30K Posts
Latest posts 5
Biogen's tau-targeting Alzheimer's therapy was linked to a 38% slowing of clinical decline at 96 weeks, strengthening the case for late-stage development despite a mixed phase 2 readout. fiercebiotech.com/biotech/biogen…
Pfizer is entering the in vivo CAR-T race with a deal worth up to $2.6 billion for three preclinical autoimmune programs from China’s Starna Therapeutics, including $330 million upfront. fiercebiotech.com/biotech/pfizer…
Marrow Therapeutics has launched with $173 million in funding to advance a preclinical therapy targeting sickle cell disease and beta thalassemia. fiercebiotech.com/biotech/marrow…
Isomorphic Labs has pulled off another massive financing, raising $5 billion in a series C just six months after securing $2.1 billion for its AI drug development platform. fiercebiotech.com/biotech/isomor…